Articles > Reference > News Wires, White Papers, and Books > Blood Weekly articles > November 2009

Article: Genzyme Reports Third-Quarter Financial Results.(Financial report)

Article from:
Blood Weekly
Article date:
November 5, 2009
Copyright

Genzyme Corp. (NASDAQ: GENZ) reported that third-quarter revenue was $1.06 billion, compared with $1.16 billion in the same period a year ago. Results reflect the impact of the temporary interruption in production of Cerezyme[R] (imiglucerase for injection) and Fabrazyme[R] (agalsidase beta) associated with the remediation of the company's Allston manufacturing facility (see also Genzyme Corp.).

GAAP net income was $16.0 million, or $0.06 per diluted share, compared with $119.6 million, or $0.42 per diluted share, in the third quarter of 2008. Non-GAAP net income was $83.9 million, or $0.31 per diluted share, compared with $151.4 million, or $0.53 per diluted ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: FDA Approves Genzyme's Fabrazyme(R); Product is First ...
PR Newswire;  April 24, 2003 ;     700+ words ... ... granted marketing approval for Fabrazyme(R) (agalsidase beta), an ... replacement therapy for Fabry disease. Fabrazyme is the first treatment approved ... inherited disorder. "FDA approval of Fabrazyme is a culmination of more than 30 ...

Article: Genzyme Receives Approval to Market Fabrazyme(TM) in ...
PR Newswire;  August 3, 2001 ;     700+ words ... ... received marketing authorization for Fabrazyme(TM) (agalsidase beta) in the European Union. Fabrazyme has been approved for long-term enzyme ... estimated 5,000 Fabry patients in Europe. Fabrazyme is currently an investigational product ...

Article: Genzyme Receives Approval to Market Fabrazyme(R) in Japan.
PR Newswire;  January 29, 2004 ;     700+ words ... ... that it has received approval to market Fabrazyme(R) (agalsidase beta) in Japan for ... disease. The company expects to launch Fabrazyme as soon as the Japanese Ministry of Health ... disease. The company completed a study of Fabrazyme in Japan in 2001. "The approval of ...

Article: GENZYME RECEIVES APPROVAL TO MARKET FABRAZYME IN EUROPE.
PR Newswire;  August 3, 2001 ;     700+ words ... ... received marketing authorisation for Fabrazyme(TM) (agalsidase beta) in the European Union. Fabrazyme has been approved for long-term enzyme ... estimated 5,000 Fabry patients in Europe. Fabrazyme is currently an investigational product ...

Article: Genzyme Successfully Completes Phase 4 Study of ...
PR Newswire;  September 9, 2004 ;     700+ words ... ... completed its principal Phase 4 study of Fabrazyme(R) (agalsidase beta) and performed ... failure, heart disease and stroke. Fabrazyme was approved in the United States under ... reports top-line results of the Phase 4 Fabrazyme study and makes no such claims. Genzyme ...

Article: FDA approves Fabrazyme, an enzyme replacement therapy.
Drug Week;  May 23, 2003 ;     700+ words ... ... has granted marketing approval for Fabrazyme (agalsidase beta), an enzyme replacement therapy for Fabry disease. Fabrazyme is the first treatment approved ... inherited disorder. "FDA approval of Fabrazyme is a culmination of more than 30 ...

Article: FDA Advisory Committee Provides Positive Review of ...
PR Newswire;  January 14, 2003 ;     700+ words ... ... its biologics license application for Fabrazyme(R) (agalsidase beta). As expected ... the FDA to vote on whether to approve Fabrazyme, which Genzyme is seeking to market ... and safety data collected in studies of Fabrazyme; endpoints used in Genzyme's pivotal ...

Article: Genzyme General Reports Progress on FDA Review of ...
PR Newswire;  December 26, 2000 ;     700+ words ... ... Biologics License Application (BLA) for Fabrazyme(TM) (agalsidase beta), an investigational ... in the marketing approval process for Fabrazyme, the FDA has requested clarification ... performance in 2001. Genzyme's BLA for Fabrazyme was accepted for review by the FDA under ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives